RESUMO
PURPOSE: We aimed to evaluate the current situation of electronic health records (EHRs) and patient registries in the oncology departments of hospitals in Spain. METHODS: This was a cross-sectional study conducted from December 2018 to September 2019. The survey was designed ad hoc by the Outcomes Evaluation and Clinical Practice Section of the Spanish Society of Medical Oncology (SEOM) and was distributed to all head of medical oncology department members of SEOM. RESULTS: We invited 148 heads of oncology departments, and 81 (54.7%) questionnaires were completed, with representation from all 17 Spanish autonomous communities. Seventy-seven (95%) of the respondents had EHRs implemented at their hospitals; of them, over 80% considered EHRs to have a positive impact on work organization and clinical practice, and 73% considered that EHRs improve the quality of patient care. In contrast, 27 (35.1%) of these respondents felt that EHRs worsened the physician-patient relationship and conveyed an additional workload (n = 29; 37.6%). Several drawbacks in the implementation of EHRs were identified, including the limited inclusion of information on both outpatients and inpatients, information recorded in free text data fields, and the availability of specific informed consent. Forty-six (56.7%) respondents had patient registries where they recorded information from all patients seen in the department. CONCLUSION: Our study indicates that EHRs are almost universally implemented in the hospitals surveyed and are considered to have a positive impact on work organization and clinical practice. However, EHRs currently have several drawbacks that limit their use for investigational purposes. CLINICAL TRIAL REGISTRATION: Not applicable.
Assuntos
Registros Eletrônicos de Saúde/estatística & dados numéricos , Oncologia/estatística & dados numéricos , Serviço Hospitalar de Oncologia/estatística & dados numéricos , Sistema de Registros/estatística & dados numéricos , Atitude do Pessoal de Saúde , Estudos Transversais , Prescrição Eletrônica/estatística & dados numéricos , Humanos , Relações Médico-Paciente , Qualidade da Assistência à Saúde , Espanha , Inquéritos e Questionários/estatística & dados numéricos , Carga de TrabalhoRESUMO
El xantoma intraóseo (XIO) es un tumor óseo benigno extremadamente raro. En la histología se caracteriza por presentar macrófagos mononucleares, abundantes células espumosas y células gigantes multinucleadas. Puede aparecer asociado a otras enfermedades (XIO secundario), principalmente a desórdenes lipídicos, o en forma aislada (XIO primario). Los XIO son lesiones líticas expansivas que a menudo se encuentran en pacientes con condiciones hiperlipidémicas. En la mayoría de los casos la evaluación inicial se realiza con radiografía, aunque otros procedimientos pueden ser necesarios para confirmar el diagnóstico. Se presenta el caso de un hombre de 48 años que consultó por lumbalgia con irradiación al miembro inferior derecho e impotencia funcional de 3 meses de evolución. Tenía hallazgos imagenológicos de XIO en el hueso ilíaco derecho, sin hiperlipidemia o lesiones preexistentes. Se llevó a cabo la extirpación total del tumor y el posterior estudio histopatológico de la pieza operatoria confirmó el diagnóstico. El tratamiento resultó exitoso. El objetivo de este artículo es describir los hallazgos clínicos e imagenológicos (radiografía, resonancia magnética, tomografía computada y medicina nuclear) de un XIO primario y su tratamiento. Además, realizamos una breve revisión de la literatura.
Abstract Intraosseous xanthoma is an extremely rare benign bone tumor. Histology shows mononuclear macrophages, abundant foam cells and multinucleated giant cells. The intraosseous xanthoma may appear associated with other diseases (secondary intraosseous xanthoma), mainly lipid disorders or without an underlying lipid disorder (primary intraosseous xanthoma). The intraosseous xanthoma is a lytic, expansive tumor, often seen in patients with hyperlipidemic conditions. In most cases, the initial evaluation is performed with X-ray, although other procedures may be necessary to confirm the diagnosis. We report the case of a man aged 48, who consulted for back pain radiating to the right leg and functional disability 3 months duration, with imaging findings in the right iliac XIO in the absence of pre-existing injuries or hyperlipidemic conditions, so surgery for total removal of the tumor was performed with histological examination of the surgical specimen, confirming the preoperative diagnosis of XIO. Such treatment resulted curative. The aim of this article is to describe the clinical, imaging findings (RX, MRI, CT, nuclear medicine) and the course of treatment of a committing the iliac primary intraosseous xanthoma a and a normolipidemic patient brief review of the literature.
Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias Ósseas/diagnóstico por imagem , Xantomatose/diagnóstico por imagem , Pelve/diagnóstico por imagem , Radiografia , Tomografia Computadorizada por Raios X , Células Espumosas/patologia , Quadril/diagnóstico por imagemRESUMO
El xantoma intraóseo (XIO) es un tumor óseo benigno extremadamente raro. En la histología se caracteriza por presentar macrófagos mononucleares, abundantes células espumosas y células gigantes multinucleadas. Puede aparecer asociado a otras enfermedades (XIO secundario), principalmente a desórdenes lipídicos, o en forma aislada (XIO primario). Los XIO son lesiones líticas expansivas que a menudo se encuentran en pacientes con condiciones hiperlipidémicas. En la mayoría de los casos la evaluación inicial se realiza con radiografía, aunque otros procedimientos pueden ser necesarios para confirmar el diagnóstico. Se presenta el caso de un hombre de 48 años que consultó por lumbalgia con irradiación al miembro inferior derecho e impotencia funcional de 3 meses de evolución. Tenía hallazgos imagenológicos de XIO en el hueso ilíaco derecho, sin hiperlipidemia o lesiones preexistentes. Se llevó a cabo la extirpación total del tumor y el posterior estudio histopatológico de la pieza operatoria confirmó el diagnóstico. El tratamiento resultó exitoso. El objetivo de este artículo es describir los hallazgos clínicos e imagenológicos (radiografía, resonancia magnética, tomografía computada y medicina nuclear) de un XIO primario y su tratamiento. Además, realizamos una breve revisión de la literatura.(AU)
Abstract Intraosseous xanthoma is an extremely rare benign bone tumor. Histology shows mononuclear macrophages, abundant foam cells and multinucleated giant cells. The intraosseous xanthoma may appear associated with other diseases (secondary intraosseous xanthoma), mainly lipid disorders or without an underlying lipid disorder (primary intraosseous xanthoma). The intraosseous xanthoma is a lytic, expansive tumor, often seen in patients with hyperlipidemic conditions. In most cases, the initial evaluation is performed with X-ray, although other procedures may be necessary to confirm the diagnosis. We report the case of a man aged 48, who consulted for back pain radiating to the right leg and functional disability 3 months duration, with imaging findings in the right iliac XIO in the absence of pre-existing injuries or hyperlipidemic conditions, so surgery for total removal of the tumor was performed with histological examination of the surgical specimen, confirming the preoperative diagnosis of XIO. Such treatment resulted curative. The aim of this article is to describe the clinical, imaging findings (RX, MRI, CT, nuclear medicine) and the course of treatment of a committing the iliac primary intraosseous xanthoma a and a normolipidemic patient brief review of the literature.(AU)
RESUMO
PURPOSE: Concurrent radio-chemotherapy (RT-CT) is the standard treatment for locally advanced head and neck squamous cell carcinoma (LA-HNSCC), but RT plus epidermal growth factor receptor (EGFR) inhibitors is an effective option when CT is not appropriate. Human papillomavirus (HPV) is associated with an improved prognosis in LA-HNSCC; however, it has not been fully studied as a prognostic factor after RT + EGFR inhibitors. EXPERIMENTAL DESIGN: Immunohistochemical expression of p16INK4A and PCR of HPV16 DNA were retrospectively analyzed in tumor blocks from 52 stage III/IV LA-HNSCC patients treated with RT + EGFR inhibitors. Disease-free survival (DFS) and overall survival (OS) were analyzed by the Kaplan-Meier method. RESULTS: DNA of HPV16 was found in six of 52 tumors (12 %) and p16 positivity in eight tumors (15 %). After a median follow-up time of 45 months (6-110), p16-positive patients treated with RT + EGFR inhibitors showed an improved DFS (2-year DFS 75 vs. 44 %, HR 0.25, 95 % CI 0.06-0.99, p = 0.047) compared with p16-negative patients. These differences were outperformed when compared by HPV16 status (2-year OS rates of 83 vs. 58 %, HR 0.17, 95 % CI 0.02-0.99, p = 0.049 and 2-year DFS rates of 83 vs. 45 %, HR 0.17, 95 % CI 0.02-0.99, p = 0.049). In the Cox regression analysis with OS as the end point, ECOG 0-1 was the only prognostic factor independently associated with a good prognosis in the multivariable analysis. CONCLUSION: In this study, p16/HPV16-positive patients with LA-HNSCC treated with RT + EGFR inhibitors showed a better survival, not confirmed in multivariate analysis.